Internal Medicine, Endocrinology, Diabetes, & Metabolism · Glendale, CA
NPI
1417911314
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
801 S Chevy Chase Dr, #102
Glendale, CA, 91205
Phone (818) 265-2242
Groups this clinician bills Medicare through
Medicare paid, 2024
$154K
2,151 services
Medicare patients, 2024
1,182
Average age 74
Drug cost, 2024
$6.4M
20,776 prescriptions
Company payments, 2025
$2,105
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Zarmen Israelian was code 99214 (office e&m - established), 904 times for 722 patients. In total Zarmen Israelian billed 2,151 services in 13 codes, and Medicare paid $154K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2012-07-11.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 904 | 722 | $93.84 | $85K |
| 99231 Hospital E&M - Subsequent | Facility | 649 | 118 | $42.41 | $28K |
| 99213 Office E&M - Established | Office | 209 | 181 | $59.35 | $12K |
| 99442 Telephone Services | Office | 96 | 83 | $57.64 | $5,534 |
| 99204 Office E&M - New | Office | 84 | 84 | $122.24 | $10K |
| 99222 Hospital E&M - Initial | Facility | 68 | 64 | $107.07 | $7,281 |
| 96372 Injection Administration | Office | 59 | 23 | $10.85 | $640 |
| 99203 Office E&M - New | Office | 41 | 41 | $75.54 | $3,097 |
| 99232 Hospital E&M - Subsequent | Facility | 18 | 17 | $68.59 | $1,235 |
By year: 2022 $240K for 3,434 services; 2023 $253K for 3,295 services; 2024 $154K for 2,151 services.
Medicare prescription drug claims, 2024
In 2024, the drug Zarmen Israelian prescribed most often to Medicare patients was Levothyroxine Sodium, with 1,958 prescriptions and refills. In total Zarmen Israelian wrote 20,776 Medicare prescriptions that cost $6.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 1,958 | 2,664 | 247 | $10K |
| Ozempic Semaglutide | 1,555 | 1,629 | 190 | $1.5M |
| Metformin Hcl Generic | 1,426 | 1,835 | 194 | $3,410 |
| Jardiance Empagliflozin | 1,102 | 1,210 | 143 | $696K |
| Trulicity Dulaglutide | 879 | 928 | 121 | $873K |
| Atorvastatin Calcium Generic | 595 | 780 | 85 | $2,051 |
| Methimazole Generic | 590 | 704 | 69 | $3,816 |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 525 | 855 | 112 | $175K |
| Glipizide Generic | 473 | 590 | 63 | $1,590 |
| Novolog Flexpen Insulin Aspart | 457 | 779 | 121 | $57K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 445 | 776 | 108 | $48K |
| Farxiga Dapagliflozin Propanediol | 436 | 485 | 65 | $272K |
| Glimepiride Generic | 363 | 437 | 43 | $1,293 |
| Ezetimibe Generic | 359 | 443 | 49 | $3,118 |
| Rosuvastatin Calcium Generic | 334 | 387 | 45 | $1,679 |
Brand drugs: 10,350 claims; generic drugs: 8,625 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Zarmen Israelian $2,105 ($2,105 in general payments such as food, travel and fees) from 26 companies. The largest payer was Amgen Inc. with $332.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 14 | $332 |
| Novo Nordisk Inc NVO | 13 | $267 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $206 |
| Dexcom, Inc. DXCM | 8 | $173 |
| Ascendis Pharma Endocrinology Inc ASND | 6 | $147 |
| Xeris Pharmaceuticals, Inc. | 7 | $131 |
| Abbvie Inc. ABBV | 4 | $91.73 |
| Lilly USA, LLC LLY | 4 | $89.96 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $86.92 |
| Abbott Laboratories ABT | 3 | $74.75 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.